In brief
In a significant move, pharmaceutical companies have agreed to reduce the prices of 15 prescription drugs under Medicare after extensive negotiations. This initiative, part of a program mandated by federal law, is expected to save taxpayers and elderly patients billions of dollars. Health Secretary Robert F. Kennedy Jr. emphasized the commitment to lowering healthcare costs for Americans, attributing these negotiations as a vital step in addressing affordability concerns. While the finalized prices will depend on individual Medicare plans, the new rates will be implemented in 2027, following a successful first round of negotiations that saved an estimated $6 billion. The recent drug price reductions include medications widely used for diabetes, asthma, and cancer treatments. Furthermore, Medicare is exploring options to expand coverage for weight-loss drugs amidst rising scrutiny over their high costs.
NEW YORK (AP) — Pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations, reductions that are expected to produce billions in savings for taxpayers and older adults, the Trump administration said.
However, the net prices revealed for a 30-day supply of each drug will not match what Medicare recipients actually pay at pharmacies, as these final amounts depend on individual plans and annual spending on prescriptions.
Health Secretary Robert F. Kennedy Jr. touted the deals as part of the administration’s efforts to address affordability concerns among Americans. The Medicare drug negotiation program that made these deals possible is mandated by law and began under President Joe Biden’s administration.
“President Trump directed us to stop at nothing to lower health care costs for the American people,” Kennedy said in a statement Tuesday evening, emphasizing the administration's commitment to providing affordable health care to seniors.
The announcement marks the completion of a second round of negotiations under a 2022 law allowing Medicare to negotiate prices for the most popular and expensive prescription drugs used by older Americans, increasing the total number of negotiated drug prices to 25. The new negotiated prices will be effective in 2027, while reduced prices for the inaugural round of 10 drugs negotiated by the Biden administration will come into effect in January.
Price Negotiations Focused on Essential Medications
The latest negotiated prices involve critical medications, including highly used GLP-1 drugs for weight loss and diabetes such as Ozempic, Rybelsus, and Wegovy. Other drugs include Trelegy Ellipta for asthma and various medications for diabetes, irritable bowel syndrome, and various cancers.
Dr. Mehmet Oz, Centers for Medicare and Medicaid Services administrator, stated that the recent negotiations delivered “substantially better outcomes for taxpayers and seniors in the Medicare Part D program.”
Under the first round of negotiations led by the Biden administration, the program was estimated to save around $6 billion on net prescription drug costs. The Trump administration claims that this new round could save the government approximately $8.5 billion, equating to about 36% in net spending savings.
Despite the savings projected, there is uncertainty regarding the actual costs Medicare beneficiaries will incur at the pharmacy, as these depend on individual factors. Nonetheless, a rule established this year limits out-of-pocket drug costs for Medicare beneficiaries to $2,000, creating some relief for those burdened with high medication expenses.
Health care researcher Spencer Perlman indicated that the Trump administration's reported improvements likely stemmed from the selection of drugs negotiated and the lessons gained from the previous year. He noted that while net drug prices are proprietary, there is evidence that suggests meaningful price concessions have been achieved for seniors.
Changes to Coverage for Obesity Treatments
Although the GLP-1 weight-loss drugs involved in the negotiations have been subject to close examination due to their high out-of-pocket costs, it remains uncertain how much coverage will expand for Medicare beneficiaries wishing to use these treatments to address obesity. Currently, Medicare restricts coverage for weight-loss medications, but a recent agreement between the Trump administration and select pharmaceutical companies foreshadows a pilot program aimed at expanding coverage for these medications for high-risk individuals.
The Trump administration has also engaged in negotiations unrelated to the Medicare framework to reduce drug costs for the broader population. However, pharmaceutical companies have voiced opposition to the Medicare drug negotiations, claiming that these policies risk future medical innovation and threaten the economy.
In the upcoming year, Medicare plans to negotiate prices for another 15 drugs, including the first wave of physician-administered medications.
